Targeted therapies for rare lung diseases


Avalyn is a clinical-stage biopharmaceutical company developing inhaled therapies to treat rare respiratory diseases, including idiopathic pulmonary fibrosis and other interstitial lung diseases. Our lead candidate, AP01, is a Phase 2b-ready inhaled formulation of pirfenidone in development for the treatment of pulmonary fibrosis.


Avalyn is developing inhaled formulations of approved medications to treat rare respiratory diseases. Our initial focus is on the treatment of Interstitial Lung Diseases, including Idiopathic Pulmonary Fibrosis, and rare diseases that have dramatic impacts on patient quality of life.



November 9, 2023

Avalyn Presents Data from its AP01 and AP02 Inhaled Therapeutics Programs for Pulmonary Fibrosis
Read more »

November 6, 2023

Avalyn Strengthens Leadership Team with Key Appointments, including Dr. Craig Conoscenti as SVP, Clinical Development, and Jim Bishop as SVP, Business Operations
Read more »

October 5, 2023

Avalyn to Participate in Multiple Upcoming Investor Conferences
Read more »

September 29, 2023

Avalyn to Provide Keynote Presentation at the Formulation & Delivery U.S. 2023 Conference
Read more »

September 27, 2023

Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies
Read more »

September 18, 2023

Avalyn Pharma’s CEO Leads Workshop on Clinical Strategy at IPF Summit
Read more »

September 12, 2023

Avalyn Pharma Presents Data Showing Favorable Tolerability and Potential of AP01 to Preserve Forced Vital Capacity in Adults with Pulmonary Fibrosis
Read more »

September 11, 2023

Avalyn Pharma Appoints Business Operations Leader, Melissa Rhodes, to the Role of Chief Operating Officer
Read more »

September 7, 2023

Avalyn Pharma’s Inhaled Pulmonary Fibrosis Programs to be Highlighted at Upcoming ERS International Congress
Read more »

August 7, 2023

Avalyn Pharma Expands Executive Team with Appointment of Howard M. Lazarus, MD, FCCP to the Role of Chief Medical Officer
Read more »

July 27, 2023

Avalyn Pharma Invited to Present at Canaccord Genuity Annual Growth Conference
Read more »

June 15, 2023

Avalyn Pharma Highlighting Inhalation Platform at Upcoming H.C. Wainwright and Hanson Wade Conferences in June
Read more »